Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT07097142
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Phase 3 · Canada, United States · 259 sites
Registry update: 23 Oct 2026
NCT07557563
Recruiting
Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma
Not applicable · Hong Kong · 1 site
Registry update: 27 Oct 2026
NCT07106762
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Phase 2/3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, Switzerland, China, Czechia, Germany, Spain, France, United Kingdom, Ireland, Israel, Italy, Japan, Netherlands, Norway, Romania, Sweden, United States · 163 sites
Registry update: 29 Jul 2026
NCT07187635
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Not applicable · China · 7 sites
Registry update: 3 Nov 2026
NCT07129993
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2/3 · Austria, China, Germany, France, Italy, Japan, United States · 95 sites
Registry update: 20 Aug 2026
NCT07124000
Recruiting
DESTINY-PANTUMOUR04
Not applicable · United States · 18 sites
Registry update: 25 Sept 2026
NCT07225374
Recruiting
Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC
Phase 2 · South Korea · 1 site
Registry update: 6 Nov 2025
NCT07514143
Recruiting
Bladder EpiCheck Product Development Study
Not applicable · United States · 2 sites
Registry update: 7 Apr 2026
NCT06919965
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Phase 3 · Argentina, Belgium, Brazil, China, Germany, Spain, France, United Kingdom, Greece, Israel, Italy, Japan, South Korea, Netherlands, United States · 121 sites
Registry update: 3 Nov 2026
NCT06503146
Recruiting
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 · United States · 1 site
Registry update: 29 Oct 2026
NCT06814496
Recruiting
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/2 · United States · 3 sites
Registry update: 6 Oct 2026
NCT07130578
Recruiting
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
Not applicable · China · 2 sites
Registry update: 3 Mar 2026
NCT07204132
Recruiting
Investigation Into the Integration of Intracavitary Cryoablation and Immunotherapy in Bladder-Preserving Therapy
Not applicable · China · 1 site
Registry update: 2 Oct 2025
NCT07202819
Recruiting
Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy
Not applicable · Egypt · 1 site
Registry update: 2 Oct 2025
NCT07321210
Recruiting
Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)
Not applicable · China · 1 site
Registry update: 25 Jun 2026
NCT07164950
Recruiting
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
Not applicable · China · 1 site
Registry update: 15 Sept 2025
NCT07202845
Recruiting
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Not applicable · Egypt · 1 site
Registry update: 2 Oct 2025
NCT07030257
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 · United States · 13 sites
Registry update: 18 Feb 2026
NCT06966024
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 · United States · 8 sites
Registry update: 18 Aug 2026
NCT07169734
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Phase 1/2 · Spain, France, Hong Kong, Italy, Netherlands, Singapore, Taiwan, United States · 41 sites
Registry update: 2 Jul 2026

Ordered by registry start date. Freshness and sponsorship never change the order.